Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06794996 · ClinicalTrials.gov registry record · Phase 2
Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities
A Phase 2 study of Proteinuric Kidney Disease, sponsored by Vertex Pharmaceuticals Incorporated.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 20
- Study locations
NCT06794996 is a Phase 2 study of Proteinuric Kidney Disease that is actively recruiting participants, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 45 participants. The trial reports 20 study locations across 8 states.
The verdict
NCT06794996, a Phase 2 study of Proteinuric Kidney Disease, is actively recruiting participants, sponsored by Vertex Pharmaceuticals Incorporated.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the efficacy, safety, and tolerability of Inaxaplin (IXP) in participants with proteinuric APOL1- mediated kidney disease (AMKD).
Conditions Studied
Interventions
- DRUG Inaxaplin
Study Locations (20)
Georgia
- Renal Associates, LLC - Columbus
- Georgia Nephrology - Decatur - Decatur
- Javara Inc./Privia Medical Group Georgia, LLC - Fayetteville - Fayetteville
- Georgia Nephrology - Lawrenceville
- Javara Inc. /Privia Medical Group Georgia, LLC - Savannah - Savannah
Florida
- Foundation for Sickle Cell Disease Research, LLC - Hollywood
- South Florida Research Institute - Lauderdale Lakes
- Schiff Center for Liver Diseases - Miami
- CTR Oakwater, LLC - Orlando
Louisiana
- Renal Associates of Baton Rouge - Baton Rouge
- LCMC Health - Metairie
- Ochsner Medical Center - New Orleans - Nephrology - New Orleans
- Northwest Louisiana Nephrology, LLC - Shreveport - Shreveport
Mississippi
- Nephrology Associates, P.C. - Columbus
- Nephrology and Hypertension Associates, LTD - Tupelo
New Jersey
- Saint Michael's Medical Center - Peter Ho Memorial Clinic - Newark
- Rutgers Doctors Office Center - Newark
Alabama
- Nephrology Consultants, LLC - Huntsville
Maryland
- Javara Inc./Privia Medical Group, LLC MidAtlantic-Silver Spring, MD - Silver Spring
Nevada
- DaVita Clinical Research - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-02-04 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06794996
The ClinicalTrials.gov registry entry for NCT06794996 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Proteinuric Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which Inaxaplin is the first listed.
NCT06794996 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Georgia, Florida, Louisiana.
Frequently Asked Questions
What is clinical trial NCT06794996 about?
NCT06794996 is a clinical study titled "Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities". The purpose of the study is to evaluate the efficacy, safety, and tolerability of Inaxaplin (IXP) in participants with proteinuric APOL1- mediated kidney disease (AMKD).
What is the current status of trial NCT06794996?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2025-02-04. Estimated completion is 2026-12-30.
What conditions does trial NCT06794996 study?
This clinical trial studies the following conditions: Proteinuric Kidney Disease.
What interventions are being tested in trial NCT06794996?
The interventions under investigation include: Inaxaplin (DRUG).
Who is sponsoring clinical trial NCT06794996?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06794996 being conducted?
This trial has 20 study locations across Alabama, Florida, Georgia, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Proteinuric Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.